Table 1. Probes where high expression is prognostic of poor outcome with an FDR <0.05.
(25–75)% is the difference in expression of the 25th and 75th percentile expression on a log scale. The Stouffer p-value was used as the ranking metric combining the p-values from each cohort.
TCGA Ovarian Broad OS Stage 3 and 4 | HAS Ovarian OS Stage 3 and 4(No TCGA) | ||||||||
---|---|---|---|---|---|---|---|---|---|
REF | Probe | p-value | HR 95% CI | (25–75)% | p-value | HR 95% CI | (25–75)% | Stouffer | FDR |
AXL | 202686_s_at | 2.29E-04 | 1.27 CI(1.12–1.45) | 1.3 | 0.001 | 1.29 CI(1.10–1.50) | 0.7 | 1.83E-06 | 0.022 |
APC | 203525_s_at | 4.92E-05 | 1.33 CI(1.16–1.52) | 0.8 | 0.017 | 1.22 CI(1.04–1.43) | 0.7 | 5.01E-06 | 0.029 |
RAB11FIP5 | 210879_s_at | 7.59E-05 | 1.29 CI(1.14–1.46) | 0.7 | 0.039 | 1.19 CI(1.01–1.40) | 0.4 | 1.82E-05 | 0.041 |
C19orf2 | 211563_s_at | 0.007 | 1.19 CI(1.05–1.35) | 1.1 | 1.85E-04 | 1.36 CI(1.16–1.60) | 0.6 | 2.92E-05 | 0.041 |
CYBRD1 | 217889_s_at | 3.91E-04 | 1.24 CI(1.10–1.40) | 2 | 0.014 | 1.21 CI(1.04–1.41) | 1.3 | 2.99E-05 | 0.041 |
PINK1 | 209019_s_at | 0.006 | 1.19 CI(1.05–1.34) | 0.7 | 4.83E-04 | 1.31 CI(1.12–1.52) | 0.5 | 4.42E-05 | 0.041 |
LRRN3 | 209840_s_at | 4.84E-05 | 1.21 CI(1.10–1.32) | 0.3 | 0.118 | 1.13 CI(0.97–1.33) | 1.8 | 4.78E-05 | 0.041 |
AQP1 | 207542_s_at | 0.005 | 1.19 CI(1.05–1.35) | 0.8 | 8.19E-04 | 1.33 CI(1.12–1.57) | 0.7 | 5.02E-05 | 0.041 |
DES | 214027_x_at | 0.005 | 1.18 CI(1.05–1.32) | 0.5 | 8.46E-04 | 1.29 CI(1.11–1.49) | 1.3 | 5.13E-05 | 0.041 |
XRCC4 | 205072_s_at | 0.053 | 1.13 CI(1.00–1.27) | 0.6 | 3.62E-06 | 1.48 CI(1.26–1.75) | 0.7 | 6.35E-05 | 0.047 |
BCHE | 205433_at | 4.09E-04 | 1.23 CI(1.10–1.37) | 0.7 | 0.033 | 1.20 CI(1.01–1.43) | 1.7 | 7.10E-05 | 0.048 |
ASAP3 | 219103_at | 1.26E-04 | 1.27 CI(1.13–1.44) | 0.6 | 0.088 | 1.14 CI(0.98–1.32) | 0.9 | 7.34E-05 | 0.048 |